Analysis of the Global Human Albumin Market and Product Pipeline : Emerging Economies and Use of Human Albumin as an Excipient Present New Growth Opportunities
Executive Summary—Key Findings
- The global human albumin demand is likely to grow at a moderate rate of % during 2013'2020 driven by the use of albumin as a drug formulation agent, sealant, medical coating, and as an imaging and vaccine stabiliser. - Human albumin production is driven by the global increase in fractionation of blood and the rising demand for human albumin in Asia-Pacific (APAC) nations such as China and India. - The human albumin market is highly consolidated and dominated by top participants, namely, CSL Behring, Grifols, Kedrion, Octapharma, and Biotest. Manufacturers are likely to adopt premium pricing to meet the emerging demand for human albumin in the non-therapeutic segment. - The human albumin market is characterised by advancements in the use of human albumin protein as a vehicle for the delivery of drugs and extension of the shelf life of drugs/biologics. - These innovations are revolutionising the standard treatment regimen by reducing the requirement for additional doses or injections, better tolerance, and improved efficacy of the drug action. - Human albumin has been widely used in clinical settings as a plasma expander or as replacement therapy. However, for over a decade, the use of human albumin as a non-therapeutic substance/excipient, that is, as a drug carrier, stabilising agent in vaccine, and as a sealant in surgeries and coatings in medical devices and diagnostic kits is being explored and developed for commercial settings.
Table Of Contents
Analysis of the Global Human Albumin Market and Product PipelineÂ Table Of Contents 1 EXECUTIVE SUMMARY